Future innovation at risk as venture capital dries up for early-stage companies
LONDON, BOSTON, SAN FRANCISCO, TOKYO (March 16, 2016) – Funding for early stage biopharma and medtech research dwindled in 2015, as investors shifted their support to more mature companies. These findings and more were released today as part of the Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate Ltd.
This venture investment trend, which began five years ago, could constrain future pharmaceutical and medtech innovation, as promising new scientific discoveries fail to progress due to lack of funding.
“Early stage investment is the lifeblood of the industry,” said Lisa Urquhart, Editor of EP Vantage. “Our 2015 reports show it’s being given to an increasingly small pool of companies, which could cause some very serious problems in the future. Both medtech and pharma need a large cohort of startup companies to hedge against failure and foster innovation. Depriving them of funding now could eventually choke the industry.”
Other key findings include:
The two reports published today offer analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2015. The reports are based on EvaluatePharma® and EvaluateMedTech® data.
To download the complimentary Pharma & Biotech 2015 in Review report, please visit www.evaluategroup.com/PharmaBiotech2015Review.
For the Medtech 2015 in Review report, please visit www.evaluategroup.com/Medtech2015Review.
About Evaluate Ltd
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our subscription services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Evaluate Custom Services provides project-based analytical and data services. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluate.com.
Issued for and on behalf of Evaluate by Instinctif Partners.
For more information please contact: firstname.lastname@example.org